Literature DB >> 14675408

FcgammaRIIB is differentially expressed during B cell maturation and in B-cell lymphomas.

Sophie Camilleri-Broët1, Lydie Cassard, Philippe Broët, Alain Delmer, Agnès Le Touneau, Jacques Diebold, Wolf Herman Fridman, Thierry Jo Molina, Catherine Sautès-Fridman.   

Abstract

FcgammaRIIB, a low affinity receptor for the Fc portion of immunoglobulin G (IgG), is thought to drive negative selection of B cells in germinal centers (GC) by inducing apoptosis upon interaction with immune complexes. Its expression was investigated by immunohistochemistry in 22 reactive lymphoid tissues and 112 B-cell lymphomas. Pre-GC mantle cells, marginal zone cells and their neoplastic counterparts expressed FcgammaRIIB. The B chronic lymphocytic leukaemia (B-CLL)/small lymphocytic lymphomas were also positive. Not detected in GC, FcgammaRIIB was expressed in 52% of follicular lymphomas and in 20% of diffuse large B cell lymphomas (DLBCL). In DLBCL, FcgammaRIIB expression was linked to transformation (P < 0.001). Re-analysis of a gene profile data set from the Lymphochip microarrays showed that FcgammaRIIB expression in the activated B-like DLBCL subgroup was higher than in the GC-like one (P < 0.04), and was associated with an adverse prognostic both in univariate (P < 0.003) and in multivariate analysis including the International Prognostic Indicator (IPI) (P < 0.01). Thus these results challenge the potential role of FcgammaRIIB during B-cell selection in GC, and suggest a prognostic value of FcgammaRIIB expression in DLBCL.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14675408     DOI: 10.1046/j.1365-2141.2003.04737.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  8 in total

1.  Integrative analysis reveals an outcome-associated and targetable pattern of p53 and cell cycle deregulation in diffuse large B cell lymphoma.

Authors:  Stefano Monti; Bjoern Chapuy; Kunihiko Takeyama; Scott J Rodig; Yansheng Hao; Kelly T Yeda; Haig Inguilizian; Craig Mermel; Treeve Currie; Ahmet Dogan; Jeffery L Kutok; Rameen Beroukhim; Donna Neuberg; Thomas M Habermann; Gad Getz; Andrew L Kung; Todd R Golub; Margaret A Shipp
Journal:  Cancer Cell       Date:  2012-09-11       Impact factor: 31.743

Review 2.  Fc gamma receptors and cancer.

Authors:  Lydie Cassard; Joël Cohen-Solal; Sophie Camilleri-Broët; Emilie Fournier; Wolf Herman Fridman; Catherine Sautès-Fridman
Journal:  Springer Semin Immunopathol       Date:  2006-11-10

Review 3.  Fc receptors and their role in immune regulation and autoimmunity.

Authors:  Toshiyuki Takai
Journal:  J Clin Immunol       Date:  2005-01       Impact factor: 8.317

Review 4.  Role of Fc Receptors as a therapeutic target.

Authors:  Atsuhiro Masuda; Masaru Yoshida; Hideyuki Shiomi; Yoshinori Morita; Hiromu Kutsumi; Hideto Inokuchi; Shigeto Mizuno; Akira Nakamura; Toshiyuki Takai; Richard S Blumberg; Takeshi Azuma
Journal:  Inflamm Allergy Drug Targets       Date:  2009-03

Review 5.  Inhibitory Fc gamma receptors: from gene to disease.

Authors:  Radu N Stefanescu; Mikhail Olferiev; Yi Liu; Luminita Pricop
Journal:  J Clin Immunol       Date:  2004-07       Impact factor: 8.317

Review 6.  Fc gamma receptors: glycobiology and therapeutic prospects.

Authors:  Jerrard M Hayes; Mark R Wormald; Pauline M Rudd; Gavin P Davey
Journal:  J Inflamm Res       Date:  2016-11-16

Review 7.  Targeting the Antibody Checkpoints to Enhance Cancer Immunotherapy-Focus on FcγRIIB.

Authors:  Ingrid Teige; Linda Mårtensson; Björn L Frendéus
Journal:  Front Immunol       Date:  2019-03-12       Impact factor: 7.561

Review 8.  Reprogramming the Constant Region of Immunoglobulin G Subclasses for Enhanced Therapeutic Potency against Cancer.

Authors:  Tae Hyun Kang; Sang Taek Jung
Journal:  Biomolecules       Date:  2020-03-01
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.